



Immune Response of People Living with HIV to COVID-19

Guest Editors:

Dr. Lemonia Skoura

Department of Microbiology,
AHEPA University Hospital,
School of Medicine, Aristotle
University of Thessaloniki, 54636
Thessaloniki, Greece

Dr. Helena C. Maltezou

Directorate of Epidemiological
Surveillance and Interventions
for Infectious Diseases, National
Public Health Organization,
Athens, Greece

Dr. Giota Lourida

Senior Consultant in Internal
Medicine and Infectious Diseases,
HIV and Infectious Diseases
Department, Evangelismos
General Hospital, 45-47,
Ypsilantou St., 10676 Athens,
Greece

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editors

Dear Colleagues,

For people living with HIV (PLWH) who experience SARS-CoV-2, limited evidence suggests a lower magnitude of humoral and cell-mediated immune responses and a shorter-duration antibody response compared to HIV-naïve individuals. Moreover, further study is needed to elucidate the immune response following vaccination among the PLWH population, since sparse data exist on the immunogenicity of non-replicating adenovirus vector, messenger RNA, or protein-based COVID-19 vaccines in PLWH. Suboptimal responses to immunization against other infections such as yellow fever, hepatitis B, influenza, polio, diphtheria, and tetanus among PLWH were also reported.

The focus of this Special Issue is on recent advances in the understanding of the host immune responses following natural infection and vaccination, as well as the immunologic processes resulting in post-acute sequelae of SARS-CoV-2 infection among PLWH. Adding new information on this population is expected to improve our knowledge of the immune response towards SARS-CoV-2 among PLWH and aid in tailored prevention and treatment modalities against COVID-19.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com